
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatm... SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address significant unmet therapeutic needs. It is engaged in developing a lead product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against a broad range of Candida and Aspergillus species, including drug-resistant strains. Show more
Période | Variation | Variation % | Ouver. | Haut | Bas | Moyenne Vol. Quot. | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | -0.07 | -6.42201834862 | 1.09 | 1.1 | 0.99 | 137852 | 1.01520039 | CS |
4 | -0.05 | -4.67289719626 | 1.07 | 1.245 | 0.99 | 161716 | 1.10709863 | CS |
12 | -0.19 | -15.7024793388 | 1.21 | 1.49 | 0.9006 | 226956 | 1.15281661 | CS |
26 | -0.41 | -28.6713286713 | 1.43 | 1.66 | 0.9006 | 182567 | 1.25946662 | CS |
52 | -0.61 | -37.4233128834 | 1.63 | 3.07 | 0.9006 | 192149 | 1.61801114 | CS |
156 | -3.09 | -75.1824817518 | 4.11 | 5.1475 | 0.9006 | 351293 | 2.49332888 | CS |
260 | 0.11 | 12.0879120879 | 0.91 | 11.3 | 0.5 | 397231 | 3.60878904 | CS |
Les dernières valeurs consultées apparaîtront dans cette boîte, vous permettant de choisir facilement les titres vus auparavant.
Assistance: support@advfn.fr
En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales